azirkitug + budigalimab

**Azirkitug + budigalimab** is a combination of two investigational monoclonal antibodies developed by AbbVie for the treatment of multiple solid tumors, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and other solid tumors. Azirkitug (ABBV-514) is an anti-CCR8 monoclonal antibody, targeting the CCR8 receptor expressed on tumor-associated regulatory T cells, aimed at modulating the tumor microenvironment and enhancing antitumor immunity. Budigalimab is a humanized IgG1 monoclonal antibody that targets programmed cell death protein 1 (PD-1), acting as an immune checkpoint inhibitor to promote T cell-mediated antitumor activity. These agents are administered via intravenous infusion, and the combination strategy is under evaluation in early-phase clinical trials for safety, pharmacokinetics, and preliminary efficacy[1][2][3][4][5].

Other names

azirkitug + budigalimabABBV-514 + budigalimab